Combination DMARD therapy with hydroxychloroquine, sulfasalazine, and methotrexate
Triple combination therapy with hydroxychloroquine, sulfasalazine, and methotrexate (MTX) has been shown in double-blind, placebo-controlled studies to be significantly superior to MTX alone (Paulus 50% responses of 77% versus 33%). In long-term follow-up studies, this therapy has now been shown to be well-tolerated with continued efficacy in the majority of patients.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
1999 |
|---|---|
| Erschienen: |
1999 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Clinical and experimental rheumatology - 17(1999), 6 Suppl 18 vom: 04. Nov., Seite S53-8 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
O'Dell, J R [VerfasserIn] |
|---|
| Themen: |
3XC8GUZ6CB |
|---|
| Anmerkungen: |
Date Completed 05.01.2000 Date Revised 12.01.2017 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM105192317 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM105192317 | ||
| 003 | DE-627 | ||
| 005 | 20231222134136.0 | ||
| 007 | tu | ||
| 008 | 231222s1999 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0351.xml |
| 035 | |a (DE-627)NLM105192317 | ||
| 035 | |a (NLM)10589358 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a O'Dell, J R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Combination DMARD therapy with hydroxychloroquine, sulfasalazine, and methotrexate |
| 264 | 1 | |c 1999 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 05.01.2000 | ||
| 500 | |a Date Revised 12.01.2017 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Triple combination therapy with hydroxychloroquine, sulfasalazine, and methotrexate (MTX) has been shown in double-blind, placebo-controlled studies to be significantly superior to MTX alone (Paulus 50% responses of 77% versus 33%). In long-term follow-up studies, this therapy has now been shown to be well-tolerated with continued efficacy in the majority of patients | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 650 | 7 | |a Sulfasalazine |2 NLM | |
| 650 | 7 | |a 3XC8GUZ6CB |2 NLM | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 650 | 7 | |a Methotrexate |2 NLM | |
| 650 | 7 | |a YL5FZ2Y5U1 |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental rheumatology |d 1989 |g 17(1999), 6 Suppl 18 vom: 04. Nov., Seite S53-8 |w (DE-627)NLM012613010 |x 0392-856X |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:1999 |g number:6 Suppl 18 |g day:04 |g month:11 |g pages:S53-8 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 1999 |e 6 Suppl 18 |b 04 |c 11 |h S53-8 | ||